首页 瑞思迈(usRMD)-基本信息

瑞思迈(usRMD)-基本信息

日报更新时间:04-17 11:30

周报更新时间:04-11 03:39

行情信息

今开价:205.63

最高价:207.82

成交量:475391.0

昨收价:204.2

最低价:204.48

最新价:207.51

行情图标
概要信息

中文名称:瑞思迈


英文名称:ResMed


行业:医疗


简介:ResMed Inc.注册于特拉华州,是一家领先的治疗、诊断和管理睡眠呼吸障碍和其他呼吸系统疾病医疗设别开发商、制造商和分销商


电话:1-858-8365000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

ResMed提供各种呼吸障碍的产品和解决方案,包括应用于医疗和消费品、通风设备、诊断产品、用于医院和家庭的面罩系统、头带和其他附件、牙科设备、便携式氧气浓缩器的技术;基于云的软件信息解决方案来管理患者数据;提供客户和业务流程解决方案。瑞思迈公司还提供加湿器,携带袋和呼吸回路;数据通信和控制产品,如EasyCare,ResLink,ResControl,ResControl II,TxControl,ResScan和ResTraxx模块,便于将数据和其他信息传输到流量发生器或从流量发生器传输数据。ResMed通过大约120个国家的分销商和直销团队,将产品销售给睡眠诊所,家庭医疗保健经销商,病人,医院,医生和第三方付款人。分销和销售地点主要包括美国、德国、法国、英国、瑞士、澳洲,产品制造地点位于新加坡、法国、美国、澳洲等。瑞思迈呼吸机:瑞思迈呼吸机(ResMed)专为家庭和睡眠中心设计,适用于OSA患者和其他需要呼吸支持的治疗情况。为治疗呼吸暂停而设计,它同时能够监测到呼吸暂停、低通气、打鼾、气流受限等事件,并能够对不同的呼吸事件自动作出反应及压力调整。发展历史: 1981年 沙利文教授首次报道CPAP治疗方法 1989年 APD 1 第一代CPAP瑞思迈呼吸机 1990年 APD 2 第二代CPAP瑞思迈呼吸机 1993年 Sullivan Ⅲ 第三代CPAP瑞思迈呼吸机 1994年 Sullivan Ⅳ 第四代CPAP瑞思迈呼吸机 1995年 Sullivan Ⅴ 第五代CPAP瑞思迈呼吸机 2000年 Sullivan S6 第六代CPAP瑞思迈呼吸机 2002年 Sullivan S7 第七代CPAP瑞思迈呼吸机 2005年 Sullivan S8 第八代CPAP瑞思迈呼吸机 2007年 Tango 系列CPAP呼吸机 2010年 瑞思迈公司推出第九代S9瑞思迈呼吸机 1994年 瑞思迈首次推出CPAP平台指数滴定法 1994年第一代AUTOSET自动压力调节呼吸机 1995年第二代AUTOSET自动压力调节呼吸机 1997年第三代AUTOSET自动压力调节呼吸机 1999年第四代AUTOSET自动压力调节呼吸机 2002年第五代AUTOSET自动压力调节呼吸机 2005年第六代AUTOSET自动压力调节呼吸机 2008年第八代AutoSet II自动压力调节呼吸机 到目前为止,瑞思迈共研发并生产了超过 50种 不同类型的面罩 1994年第一代VPAP双水平无创正压呼吸机 1996年第二代VPAP双水平无创正压呼吸机 2002年第三代VPAP双水平无创正压呼吸机 2008年VPAP Auto 双水平全自动呼吸机 2003年世界首创变压双水平无创正压呼吸机AutoSet CS2 2001年兼并德国呼吸机专业制造公司MAP 2002年兼并美国压缩机专业公司SMI 2005年兼并法国呼吸机专业制造公司Saime。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-14 Douglas (Robert Andrew) President Sell 804 124.50
2019-07-14 Douglas (Robert Andrew) President Buy 3307 43.63
2019-07-14 Douglas (Robert Andrew) President Sell 3307 124.50
2019-07-07 Farrell (Michael J.) Chief Executive Officer Sell 6651 123.76
2019-07-07 Farrell (Michael J.) Chief Executive Officer Buy 6651 43.63
2019-07-02 Pendarvis (David Brian) Officer Sell 4131 123.83
2019-07-02 Pendarvis (David Brian) Officer Buy 4367 52.02
2019-07-02 Pendarvis (David Brian) Officer Sell 236 124.40
2019-06-30 Sandercock (Brett A) Chief Financial Officer Sell 3000 123.17
2019-06-30 Hollingshead (James R) Officer Buy 800 58.24
2019-06-30 Hollingshead (James R) Officer Sell 800 123.17
2019-06-30 Hollingshead (James R) Officer Sell 800 123.17
2019-06-16 Douglas (Robert Andrew) President Sell 847 118.44
2019-06-16 Douglas (Robert Andrew) President Buy 3307 43.63
2019-06-16 Douglas (Robert Andrew) President Sell 3307 118.44
2019-06-09 Farrell (Michael J.) Chief Executive Officer Sell 1440 117.56
2019-06-09 Farrell (Michael J.) Chief Executive Officer Sell 5211 118.32
2019-06-09 Farrell (Michael J.) Chief Executive Officer Buy 6651 43.63
2019-06-02 Hollingshead (James R) Officer Sell 800 114.01
2019-06-02 Hollingshead (James R) Officer Buy 800 58.24
2019-06-02 Hollingshead (James R) Officer Sell 800 114.01
2019-06-02 Pendarvis (David Brian) Officer Buy 4367 52.02
2019-06-02 Pendarvis (David Brian) Officer Sell 4367 114.01
2019-05-30 Pendarvis (David Brian) Officer Sell 239 114.12
2019-05-29 Sandercock (Brett A) Chief Financial Officer Sell 3000 112.34

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Putnam Investment Management, LLC 1161179 0.81% -30918 -2.59% 2019-07-31
Capital Research and Management Company 5765000 4.01% -611100 -9.58% 2019-07-31
Capital World Investors 5765000 4.02% -489781 -7.83% 2019-03-31
State Street Corporation 6275750 4.38% 187256 3.08% 2019-03-31
Fidelity Management and Research Company 6303913 4.40% -1090102 -14.74% 2019-03-31
FMR Inc 6642540 4.63% -1002175 -13.11% 2019-03-31
WCM Investment Management 7059797 4.92% 2735434 63.26% 2019-03-31
BlackRock Inc 11980416 8.35% 216173 1.84% 2019-03-31
Vanguard Group Inc 15114773 10.54% 249539 1.68% 2019-03-31
Fidelity Management & Research Company 5184828 3.61% -1938451 -27.21% 2019-07-31
Baillie Gifford & Co Limited. 4797781 3.35% -48319 -1.00% 2019-03-31
BlackRock Fund Advisors 4296231 2.99% -3497450 -44.88% 2019-07-31
Invesco Ltd (OFI / OppenheimerFunds) 1356361 0.94% 9664 0.72% 2019-07-31
State Street Global Advisors (Aus) Ltd 1555293 1.08% -69746 -4.29% 2019-07-31
Northern Trust Investments N A 1954810 1.36% 276097 16.45% 2019-03-31
Northern Trust Corp 1954810 1.36% 276097 16.45% 2019-03-31
WCM Investment Management, LLC 2013904 1.40% 797925 65.62% 2019-07-31
Geode Capital Management, LLC 2030769 1.42% -2010829 -49.75% 2019-03-31
State Street Global Advisors 2349094 1.64% 7737 0.33% 2019-07-31
Vanguard Investments Australia Ltd 4010107 2.79% 10429 0.26% 2019-07-31
BlackRock Asset Management Canada Ltd 4487190 3.13% 2823 0.06% 2019-05-31
BlackRock Japan Co Ltd 2112070 1.47% 1892 0.09% 2019-05-31
Bank of New York Mellon Corp 1367169 0.95% -265602 -16.27% 2018-12-31
JPMorgan Chase & Co 1344343 0.94% -800 -0.06% 2018-09-30
Deutsche Bank AG 1070593 0.75% -296882 -21.71% 2018-12-31
First State Investment Mgmt (UK) Ltd 1961186 1.38% -- -- 2018-12-31
Equity Trustees Ltd 1135975 0.80% 1135975 -- 2018-11-30
BlackRock Institutional Trust Company NA 3501853 2.46% -571781 -14.04% 2018-06-30
State Street Corp 5517084 3.87% -96815 -1.72% 2018-06-30
Congress Asset Management Co 989557 0.69% -39759 -3.86% 2018-06-30
Millennium Management LLC 870142 0.61% 100606 13.07% 2018-06-30
Charles Schwab Investment Management Inc 813087 0.57% 87893 12.12% 2018-06-30
J.P. Morgan Investment Management Inc 768122 0.54% 247311 47.49% 2018-06-30
Mellon Capital Management Corporation 738754 0.52% -17085 -2.26% 2018-06-30
Legal & General Group PLC 703266 0.49% -33876 -4.60% 2018-06-30
Security Investors, LLC 587689 0.42% -196 -0.03% 2018-09-14
American Capital Management Inc 643218 0.45% 1115 0.17% 2018-06-30
Morgan Stanley & Co Inc 626236 0.44% 199449 46.73% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 614304 0.43% 592774 2753.25% 2018-06-30
Mitsubishi UFJ Trust & Banking Corp 557738 0.39% -7256 -1.28% 2018-06-30
Goldman, Sachs & Co. 477070 0.33% -215479 -31.11% 2018-06-30
Guggenheim Capital LLC 637774 0.45% -84706 -11.72% 2018-03-31
NORGES BANK 1099025 0.77% -342353 -23.75% 2017-12-31
Matthews International Cap Mgmt LLc 728400 0.51% -69000 -8.65% 2017-12-31
BlackRock Advisors LLC 591786 0.41% -- -- 2018-02-28
Commonwealth Bank of Australia 1977179 1.39% -3739 -0.19% 2017-09-30
State Street Global Markets, LLC 1629988 1.15% 45902 2.90% 2016-12-31
Renaissance Technologies Corp 1421600 1.01% 632900 80.25% 2016-09-30
Panagora Asset Management Inc 1197693 0.85% 121020 11.24% 2016-09-30
Columbia Wanger Asset Management LLC 1023346 0.73% -22653 -2.17% 2016-09-30
Vanguard 8910836 9.00% 443670524 0.10% 1999-11-30
Capital Research Global Investors 9591200 9.00% 477545848 0.10% 1999-11-30
BlackRock, Inc. 9983144 9.00% 497060740 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street S&P 500 Index Fund 621118 0.43% 11700 1.92% 2019-07-31
Vanguard Total Stock Market Index Fund 3943915 2.75% 10287 0.26% 2019-06-30
Vanguard Mid-Cap Index Fund 3493025 2.43% 51075 1.48% 2019-06-30
Vanguard 500 Index Fund 2822650 1.96% 30285 1.08% 2019-06-30
WCM Focused International Growth Fund 2013904 1.40% 797925 65.62% 2019-04-30
American Funds Growth Fund of Amer 2010000 1.40% -- -- 2019-06-30
American Funds American Balanced Fund 1635000 1.14% -- -- 2019-06-30
SPDR 1590820 1.11% -4386 -0.27% 2019-07-31
American Funds Fundamental Invs 1365000 0.95% -- -- 2019-06-30
Vanguard Institutional Index Fund 1338885 0.93% -10291 -0.76% 2019-06-30
Invesco Oppenheimer Intl Gr Fd 1200570 0.84% -- -- 2019-06-30
iShares US Medical Devices ETF 622554 0.43% 3916 0.63% 2019-07-30
Health Care Select Sector SPDR 727036 0.51% 5760 0.80% 2019-07-31
American Funds IS 755000 0.53% -- -- 2019-06-30
Fidelity 800000 0.56% -- -- 2019-06-30
Vanguard Mid-Cap Growth Index Fund 912995 0.64% 36664 4.18% 2019-06-30
Vanguard Growth Index Fund 1024634 0.71% 35113 3.55% 2019-06-30
iShares Core S&P 500 ETF 1051477 0.73% -516 -0.05% 2019-07-30
BlackRock Health Sciences Opps Port 700500 0.49% -- -- 2019-05-31
iShares Core MSCI AllCntry Wld exCan ETF 1056035 0.74% 946 0.09% 2019-05-30
iShares MSCI World ETF 1056035 0.74% 946 0.09% 2019-05-30
iShares Core S&P US Total Market ETF 1056035 0.74% 946 0.09% 2019-05-30
iShares S&P 500 ETF 1056035 0.74% 946 0.09% 2019-05-30
iShares Core S&P 500 ETF (CAD-Hedged) 1056035 0.74% 946 0.09% 2019-05-30
iShares Core MSCI Kokusai ETF 1056035 0.74% 946 0.09% 2019-05-30
Undrly L&G Pen PMC Diversified 603406 0.42% 603406 -- 2018-09-30
VA CollegeAmerica Fundamental Inv 2176700 1.52% -300000 -12.11% 2018-12-31
OH Putnam Fidelity Spartan 500 Index 1067547 0.74% 30889 2.98% 2019-01-31
VA CollegeAmerica The Gr Fd of Amer 1510000 1.05% -- -- 2018-12-31
VA CollegeAmerica Amer Blcd Fd 1313000 0.92% -- -- 2018-12-31
Baillie Gifford Global Alpha Growth Fund 577270 0.40% -28442 -4.70% 2018-11-30
Undrly L&G Diversified Life 603406 0.42% 603406 -- 2018-09-30
American Funds Washington Mutual Fund 970000 0.68% -2206900 -69.47% 2018-09-30
OMI IM GBP FirstState Asia Pacific Ldrs 1961186 1.38% -- -- 2017-10-31
Stewart Investors Asia Pacific Ldrs Fd 1961186 1.38% -- -- 2017-10-31
BlackRock Health Sciences Opps Inv A 590500 0.41% -- -- 2018-07-31
VA CollegeAmerica Fundamental Invs 529E 3999783 2.80% -42917 -1.06% 2018-06-30
Vanguard Total Stock Mkt Idx 3584253 2.51% 12032 0.34% 2018-07-31
Vanguard Mid Cap Index I 3384844 2.37% 23766 0.71% 2018-07-31
VA CollegeAmerica WA Mutual 529B 3176900 2.23% -38100 -1.19% 2018-06-30
Vanguard 500 Index Inv 2584331 1.81% 3081 0.12% 2018-07-31
VA CollegeAmerica Amercn Bal 529E 1999200 1.40% -35800 -1.76% 2018-06-30
Vanguard Institutional Index I 1380710 0.97% 1153 0.08% 2018-07-31
VA CollegeAmerica Grth Fund of Amer 529F 1510000 1.06% -- -- 2018-06-30
iShares US Medical Devices 580067 0.41% 2148 0.37% 2018-09-12
Fidelity VIP Contrafund Inv 621100 0.44% 34013 5.79% 2018-07-31
American Funds NVIT Growth II 755000 0.53% -- -- 2018-06-30
Vanguard Mid-Cap Growth ETF 866978 0.61% 3864 0.45% 2018-07-31
Fidelity Spartan 950806 0.67% 11215 1.19% 2018-07-31
Vanguard Growth Index Inv 1005361 0.70% -2811 -0.28% 2018-07-31
Matthews Asian Growth & Inc Investor 589000 0.41% -- -- 2017-09-30
iShares Russell 1000 Growth 435840 0.31% -- -- 2017-12-28
Vanguard Extended Market Idx Inv 1669434 1.18% 49970 3.09% 2016-12-31
iShares S&P Mid-Cap 400 Growth 628993 0.45% 983 0.16% 2017-02-07
Columbia Acorn Z 666609 0.47% -41557 -5.87% 2016-12-31
Vanguard Explorer Inv 503619 0.36% -106930 -17.51% 2016-09-30
iShares S&P Mid-Cap 400 Value 385850 0.28% 930 0.24% 2017-02-07
Principal MidCap S&P 400 Index SP 426768 0.30% 1198 0.28% 2016-12-31
Vanguard International Growth Fund 765000 0.50% 765000 -- 2015-06-30
VA CollegeAmerica Growth Fund of America 3210000 2.30% -- -- 2015-09-30
iShares Core S&P Mid-Cap (AU) 2428426 1.70% -3295 -0.10% 2015-11-10
VA CollegeAmerica American Mutual 1800000 1.30% -- -- 2015-09-30
AXA Financial First State Asia Pac Ldr 1775109 1.30% -- -- 2015-07-31
Vanguard Extended Market Index Fund 1426214 1.00% -33552 -2.30% 2015-09-30
SPDR® S&P MIDCAP 400 ETF 1373259 1.00% -14999 -1.10% 2015-09-30
VA CollegeAmerica Cap World Gr and Inc 5526000 3.90% -- -- 2015-09-30
SSgA - S&P Mid-Cap Index Strategy Tr 924542 0.70% 5000 0.50% 2015-06-30
Fidelity® Select Health Care Portfolio 900000 0.60% -- -- 2015-09-30
Fidelity® Select Medical Equip & Systems 777264 0.60% -- -- 2015-09-30
Fidelity® Series International Growth 1009400 0.70% -- -- 2015-09-30

David Brian Pendarvis Presently, David Brian Pendarvis occupies the position of Secretary, CAO & Global General Counsel at ResMed, Inc. He is also on the board of 6 other companies. In his past career Mr. Pendarvis held the position of Partner at Gibson, Dunn & Crutcher LLP and Partner at Gray Cary Ware & Freidenrich LLP. Mr. Pendarvis received an undergraduate degree from Rice University, a graduate degree from the University of San Diego and a graduate degree from The University of Texas School of Law.
Brett A. Sandercock Mr. Brett A. Sandercock is a CFO & Principal Accounting Officer at ResMed, Inc. and a Non-Executive Chairman at Osteopore Ltd. Mr. Sandercock was previously employed as a Manager-Financial Accounting & Group Reporting by Norton Abrasives, Inc., a Principal by Saint-Gobain Abrasives, Inc., a Group Management Accountant by Healthcare of Australia Pty Ltd., a Principal by PricewaterhouseCoopers (Australia), and a Non-Executive Director by CAP-XX Ltd. He received his undergraduate degree from Macquarie University.
Robert Andrew Douglas Currently, Robert Andrew Douglas occupies the position of President & Chief Operating Officer at ResMed, Inc. and President & Chief Operating Officer at ResMed (UK) Ltd. (a subsidiary of ResMed, Inc.). He is also on the board of San Diego Regional Economic Development Corp., The Australian Science Media Centre and EvoNexus. Mr. Douglas previously was General Manager-Strategy & New Business at Keycorp Pty Ltd. Mr. Douglas received an MBA from Macquarie University and an undergraduate degree from The University of New South Wales.
Robert Andrew Douglas Ms. Constance C. Bienfait is a Director-Investor Relations at ResMed, Inc. Ms. Bienfait was previously employed as Executive Director-Corporate Communications by Kos Pharmaceuticals, Inc., Vice President-Investor Relations by Metabasis Therapeutics, Inc., and Vice President-Investor Relations by Nabi Biopharmaceuticals. She received her undergraduate degree from Trinity College (Connecticut).
Michael J. Farrell Presently, Michael J. Farrell occupies the position of Chief Executive Officer & Director at ResMed, Inc. and Chief Executive Officer of ResMed (UK) Ltd. (a subsidiary of ResMed, Inc.). He is also on the board of 9 other companies. In his past career he occupied the position of Process Engineer at BHP Group Ltd., Manager-Chemicals Practice at Arthur D. Little, Inc., Consultant & Business Analyst at Genzyme Corp. and Principal at The Dow Chemical Co. Mr. Farrell received an undergraduate degree from The University of New South Wales, a graduate degree from Massachusetts Institute of Technology and an MBA from MIT Sloan School of Management.
John P. Wareham John P. Wareham is a businessperson who has been at the helm of 5 different companies is on the board of ResMed, Inc. Mr. Wareham previously held the position of Chairman of STERIS Plc and Non-Executive Chairman at STERIS Corp. (a subsidiary of STERIS Plc), Chairman of Beckman Coulter, Inc., President for Norden Laboratories, Inc. and Chairman for Advanced Medical Technology Association. John P. Wareham received an undergraduate degree from Creighton University and an MBA from Washington University in St. Louis.
Ronald R. Taylor Founder of Pyxis Corp., Ronald R. Taylor is a businessperson who has been at the helm of 5 different companies and holds the position of Chairman of Tillster, Inc. and President at Tamarack Bay LLC. Mr. Taylor is also on the board of ResMed, Inc., Safe Life Corp. and CONNECT. In his past career he occupied the position of Chairman for Asteres, Inc., General Partner of Enterprise Partners Venture Capital, Chairman, President & Chief Executive Officer at Pyxis Corp., Principal at Hybritech, Inc., Principal at Allergan Pharmaceuticals Ltd., Inc. and Chairman at ResMed Foundation. Ronald R. Taylor received an undergraduate degree from the University of Saskatchewan and a graduate degree from the University of California, Irvine.
Peter C. Farrell Dr. Peter C. Farrell is a Chairman at Arcturus Therapeutics Holdings, Inc., a Member at National Academy of Engineering, a Member at The Order of Australia Association Ltd., a Non-Executive Chairman at ResMed, Inc., a Chairman at Waveguide Corp. and a Chairman-Innovation & Entrepreneurship at The University of New South Wales. He is on the Board of Directors at Evolus, Inc., The Scripps Research Institute, Everyone Counts, Inc., Mikroscan Technologies, Inc., Protostar, Inc., The Reason Foundation and University of California San Diego. Dr. Farrell was previously employed as a President & Trustee by Museum of Contemporary Arts San Diego, a Non-Executive Director by Telesso Technologies Ltd., an Independent Non-Executive Director by Pharmaxis Ltd., an Independent Director by NuVasive, Inc., a Non-Executive Chairman by QRxPharma Ltd., a Chairman-Executive Council by Harvard Medical School, a Managing Director by Baxter Center for Medical Research Pty Ltd., a Vice President-Research & Development by Baxter Healthcare Corp. (Japan), and a Foundation Director by Graduate School of Biomedical Engineering. He also served on the board at California Healthcare Institute, CardioDynamics International Corp. and CONNECT. He received his undergraduate degree from The University of Sydney, a graduate degree from Massachusetts Institute of Technology, a doctorate degree from The University of New South Wales and a doctorate degree from the University of Washington.
Christopher Graham Roberts Christopher Graham Roberts is a businessperson who has been the head of 5 different companies and currently holds the position of Non-Executive Chairman at OncoSil Medical Ltd. He is also on the board of Centenary Institute and Clarity Pharmaceuticals Pty Ltd. and Professor at The University of New South Wales, Professor at King's College London, Member of Innovation Australia and Professor at Arizona State University. In his past career he held the position of President, CEO & Executive Director at Cochlear Ltd., President at BGS Medical, Chairman for Sirtex Medical Ltd., Member of National Health & Medical Research Council and Chairman for Research Australia Ltd. Dr. Roberts received a doctorate and an MBA from Macquarie University and a doctorate and an undergraduate degree from The University of New South Wales.
Gary W. Pace Founder of QRxPharma Ltd., Transcend Therapeutics, Inc. and Sova Pharmaceuticals, Inc., Gary W. Pace occupies the position of Chairman at Sova Pharmaceuticals, Inc. Dr. Pace is also Professor at The University of Queensland and on the board of 11 other companies. In the past Dr. Pace occupied the position of Chairman & Chief Executive Officer of Waratah Pharmaceuticals, Inc., President & Chief Executive Officer of SkyePharma Canada, Inc., President & Chief Executive Officer for Transcend Therapeutics, Inc., Senior Vice President-Research & Development at Clintec and Independent Non-Executive Director at QRxPharma Ltd. Dr. Pace received an undergraduate degree from The University of New South Wales and a doctorate from Massachusetts Institute of Technology.
Richard Sulpizio Richard Sulpizio is a businessperson who has been at the head of 8 different companies is on the board of CA, Inc. and ResMed, Inc. and Chairman of Danny Thompson Memorial Leukemia Foundation, Inc. Mr. Sulpizio previously was President at FLO TV, Inc., President, Chief Operating Officer & Director at QUALCOMM, Inc. President & Chief Executive Officer for Media FLO USA, Inc. President for QUALCOMM Wireless Business Solutions and President of QUALCOMM Communications UK Ltd. (which are all subsidiaries of QUALCOMM, Inc.), President at Qualcomm Ltd., Principal at Unisys Corp., Principal at Fluor Corp. and President & Chief Executive Officer at Astrata Europe Holdings BV. Mr. Sulpizio received an undergraduate degree from California State University-Los Angeles and a graduate degree from the University of Southern California.
Robert Andrew Douglas Ms. Constance C. Bienfait is a Director-Investor Relations at ResMed, Inc. Ms. Bienfait was previously employed as Executive Director-Corporate Communications by Kos Pharmaceuticals, Inc., Vice President-Investor Relations by Metabasis Therapeutics, Inc., and Vice President-Investor Relations by Nabi Biopharmaceuticals. She received her undergraduate degree from Trinity College (Connecticut).
Karen Drexler Karen Drexler is an entrepreneur and businessperson who founded Medivoce, Inc., Cellscape Corp. and Amira Medical, Inc. and who has been at the head of 5 different companies. Currently, she holds the position of Executive Chairman at Cellscape Corp., Chief Executive Officer for Sandstone Diagnostics, Inc. and President & Director at Medivoce, Inc. Karen Drexler is also on the board of 7 other companies. Ms. Drexler previously was Chairman of Hygieia, Inc., Principal at LifeScan, Inc. and President & Chief Executive Officer for Amira Medical, Inc. Ms. Drexler received an undergraduate degree from Princeton University and an MBA from Stanford Graduate School of Business.
Jan de Witte Currently, Jan de Witte holds the position of Chief Executive Officer & Director at Barco NV. He is also on the board of ResMed, Inc. and X2O Media, Inc. He previously was President & CEO-Healthcare IT Business at GE Healthcare Ltd. He received a graduate degree from Katholieke Universiteit Leuven and an MBA from Harvard Business School.
Carlos M. Nunez Presently, Carlos M. Nunez holds the position of Chief Medical Officer for ResMed, Inc. He is also Member of American Medical Association, Member of European Society of Anaesthesiology, Adjunct Professor at San Diego State University, Member of American Society of Anesthesiologists, Member of Society of Critical Care Medicine, Member of Health Management Academy, Member of European Society of Intensive Care Medicine and Associate Director at Biomedical Informatics Research Center. Dr. Nunez previously held the position of Chief Physician Executive at UnitedHealth Group, Inc. and Chief Physician Executive at Picis, Inc. (a subsidiary of UnitedHealth Group, Inc.), Senior Vice President of Becton, Dickinson & Co. and Chief Medical Officer & Senior VP-Medical Affairs at CareFusion Corp. (a subsidiary of Becton, Dickinson & Co.) and Director-Education & Research at Carolinas Medical Center-Northeast. He received a doctorate from The University of Miami Leonard M. Miller School of Medicine.
Carol J. Burt Carol J. Burt is Treasurer & Director at Colorado Historical Society and Chairman at The Nature Conservancy in Colorado. She is also on the board of ResMed, Inc., Welldynerx, Inc. and IQVIA Holdings, Inc. and Principal at Burt-Hilliard Investments and Member of Women Corporate Directors. She previously occupied the position of Senior VP-Corporate Finance & Development at Anthem, Inc., Advisor at Psilos Group Managers LLC, MD & Head-Health Care Investment Banking Group at Chase Securities, Inc., Treasurer & Senior Vice President-Finance at American Medical Response, Inc. and Chairman for Women's Foundation of Colorado. Carol J. Burt received an undergraduate degree from the University of Houston.
Geoff Neilson Geoff Neilson is Senior Vice President-Global Supplier Alliance at ResMed, Inc. In his past career Mr. Neilson was Chief Executive Officer for Milvella Ltd. and Director-Clinical Studies at Telectronics Pacing Systems, Inc. He received an undergraduate degree from Heriot-Watt University.
Carol J. Burt Carol J. Burt is Treasurer & Director at Colorado Historical Society and Chairman at The Nature Conservancy in Colorado. She is also on the board of ResMed, Inc., Welldynerx, Inc. and IQVIA Holdings, Inc. and Principal at Burt-Hilliard Investments and Member of Women Corporate Directors. She previously occupied the position of Senior VP-Corporate Finance & Development at Anthem, Inc., Advisor at Psilos Group Managers LLC, MD & Head-Health Care Investment Banking Group at Chase Securities, Inc., Treasurer & Senior Vice President-Finance at American Medical Response, Inc. and Chairman for Women's Foundation of Colorado. Carol J. Burt received an undergraduate degree from the University of Houston.
James Hollingshead Dr. James Hollingshead is a President-Sleep Business at ResMed, Inc. He is on the Board of Directors at Insulet Corp. and Consumer Sleep Solutions LLC. Dr. Hollingshead was previously employed as a Senior Partner by Deloitte Consulting LLP and a Managing Partner-West Coast Division by The Monitor Group, Inc. He received his undergraduate degree from Stanford University, a graduate degree from the University of California, Berkeley and a doctorate degree from the University of California, Berkeley.
James Hollingshead Dr. James Hollingshead is a President-Sleep Business at ResMed, Inc. He is on the Board of Directors at Insulet Corp. and Consumer Sleep Solutions LLC. Dr. Hollingshead was previously employed as a Senior Partner by Deloitte Consulting LLP and a Managing Partner-West Coast Division by The Monitor Group, Inc. He received his undergraduate degree from Stanford University, a graduate degree from the University of California, Berkeley and a doctorate degree from the University of California, Berkeley.
James Hollingshead Ms. Anne Reiser is President-Europe at ResMed, Inc. Ms. Reiser was previously employed as a Principal by Hollister, Inc. and a Principal by Medtronic, Inc. She received her graduate degree from Ecole Sup�0�1�0�8rieure de Commerce de Clermont-Ferrand and a graduate degree from Universit�0�1�0�8 Blaise Pascal.
Carol J. Burt Mr. Richie McHale is Chief Human Resources Officer at ResMed, Inc. Mr. McHale was previously employed as a Member-Management Board by The Association of the British Pharmaceutical Industry.
Raj Sodhi Founder of ResMed Halifax, Inc. and TransActive Ecommerce Solutions, Inc., Raj Sodhi is President-SaaS Business at ResMed, Inc. Mr. Sodhi previously occupied the position of Chief Technology Officer of TransActive Ecommerce Solutions, Inc., Chief Technology Officer at Skipjack Financial Services, Inc. and President at ResMed Halifax, Inc. He received an MBA and an undergraduate degree from Dalhousie University.
Bobby Ghoshal Presently, Bobby Ghoshal holds the position of Chief Technology Officer at ResMed, Inc. Mr. Ghoshal previously was Chief Operating Officer of Brightree LLC. He received an MBA from Arizona State University and an undergraduate degree from National Institute of Technology (Calicut).
Nupur Bhushan Nupur Bhushan is Chief People Officer for ResMed, Inc. In the past she held the position of Director-Asia Pacific Compensation & Benefits at International Business Machines Corp. Ms. Bhushan received an MBA from Goa Institute of Management and an undergraduate degree from the University of Delhi.
Hemanth Reddy Hemanth Reddy is Chief Strategy Officer at ResMed, Inc. Mr. Reddy previously was Principal at Monitor Group (California). Mr. Reddy received an MBA from Kellogg School of Management and an undergraduate degree from Cornell University College of Engineering.
Harjit Gill Harjit Gill is on the board of ResMed, Inc.

量化对比

全部评论 1

  • 【特斯拉CEO马斯克:将向纽约医院提供其他制造商生产的呼吸机】特斯拉首席执行官马斯克在推特上表示,特斯拉正在与美敦力公司合作生产呼吸机,但是鉴于纽约的“紧迫”需求,该公司将从今晚开始提供其他制造商生产的呼吸机。马斯克称,特斯拉将向纽约的医院交付ResMed、飞利浦和美敦力生产的呼吸机。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐